Aligos Therapeutics (ALGS) Profit After Tax (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Profit After Tax came in at -$30000.0 in Q1 2026, down 100.07% YoY from $43.1 million in Q1 2025, and down 100.69% on a QoQ basis from $4.3 million in Q4 2025.
Aligos Therapeutics (ALGS) Profit After Tax (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Profit After Tax data on file, last reported at -$30000.0 in Q1 2026.
- Quarterly Profit After Tax fell 100.07% year-over-year to -$30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.3 million (up 74.62% YoY) and the FY2025 annual result came in at $17000.0, up 100.01% from the prior year.
- Profit After Tax declined to -$30000.0 in Q1 2026, from $4.3 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $59.8 million in Q4 2023 to a low of -$131.3 million in Q4 2024.
- A 5-year average of -$11.3 million and a median of -$248000.0 in 2022 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax tumbled 9116.53% — and 2024, when it jumped 1000.0%.
- Tracing ALGS's Profit After Tax over 5 years: stood at -$21.9 million in 2022, then jumped by 373.39% to $59.8 million in 2023, then tumbled by 319.5% to -$131.3 million in 2024, then surged by 103.3% to $4.3 million in 2025, then slumped by 100.69% to -$30000.0 in 2026.
- The last three Profit After Tax figures came in at -$30000.0 (Q1 2026), $4.3 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | -1.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.51 Mn |
| Mar 31, 2026 | -30,000.00 |
| Dec 31, 2025 | 4.33 Mn |
| Sep 30, 2025 | -31.54 Mn |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | 43.08 Mn |
| Dec 31, 2024 | -131.34 Mn |
| Sep 30, 2024 | -19.18 Mn |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | -34.86 Mn |
| Dec 31, 2023 | 59.84 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -2,000.00 |
| Mar 31, 2023 | -22.86 Mn |
| Dec 31, 2022 | -21.89 Mn |
| Sep 30, 2022 | -18.62 Mn |
| Jun 30, 2022 | -154,000.00 |
| Mar 31, 2022 | -248,000.00 |
| Dec 31, 2021 | -37.71 Mn |
| Sep 30, 2021 | -33.12 Mn |